Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

273 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.
Soria JC, Cortes J, Massard C, Armand JP, De Andreis D, Ropert S, Lopez E, Catteau A, James J, Marier JF, Beliveau M, Martell RE, Baselga J. Soria JC, et al. Among authors: armand jp. Ann Oncol. 2012 Feb;23(2):463-71. doi: 10.1093/annonc/mdr137. Epub 2011 May 16. Ann Oncol. 2012. PMID: 21576284 Free article. Clinical Trial.
Molecular targeting: targeting angiogenesis in solid tumors.
Soria JC, Fayette J, Armand JP. Soria JC, et al. Among authors: armand jp. Ann Oncol. 2004;15 Suppl 4:iv223-7. doi: 10.1093/annonc/mdh930. Ann Oncol. 2004. PMID: 15477311 Free article. Review. No abstract available.
Targeting angiogenesis with oral agents.
Besse B, Armand JP, Soria JC. Besse B, et al. Among authors: armand jp. Ann Oncol. 2006 Sep;17 Suppl 10:x71-5. doi: 10.1093/annonc/mdl240. Ann Oncol. 2006. PMID: 17018755 Free article. Review. No abstract available.
[Targeting angiogenesis in oncology].
Fayette J, Soria JC, Armand JP. Fayette J, et al. Among authors: armand jp. Pathol Biol (Paris). 2006 May;54(4):199-205. doi: 10.1016/j.patbio.2004.11.003. Epub 2005 Jan 20. Pathol Biol (Paris). 2006. PMID: 16753494 Review. French.
Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.
Soria JC, Cortes J, Massard C, Armand JP, De Andreis D, Ropert S, Lopez E, Catteau A, James J, Marier JF, Beliveau M, Martell RE, Baselga J. Soria JC, et al. Among authors: armand jp. Ann Oncol. 2019 Jun 1;30(6):1020. doi: 10.1093/annonc/mdy532. Ann Oncol. 2019. PMID: 30624604 Free article. No abstract available.
Nasopharyngeal carcinomas: an update.
Spano JP, Busson P, Atlan D, Bourhis J, Pignon JP, Esteban C, Armand JP. Spano JP, et al. Among authors: armand jp. Eur J Cancer. 2003 Oct;39(15):2121-35. doi: 10.1016/s0959-8049(03)00367-8. Eur J Cancer. 2003. PMID: 14522369 Review.
Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.
Faivre S, Le Chevalier T, Monnerat C, Lokiec F, Novello S, Taieb J, Pautier P, Lhommé C, Ruffié P, Kayitalire L, Armand JP, Raymond E. Faivre S, et al. Among authors: armand jp. Ann Oncol. 2002 Sep;13(9):1479-89. doi: 10.1093/annonc/mdf219. Ann Oncol. 2002. PMID: 12196375 Free article. Clinical Trial.
273 results